As part of the University at Buffalo, we are dedicated to high quality academic research, with a focus on translational use of quantitative neuroimaging metrics in neurological diseases and disorders like MS, Alzheimer’s, and stroke. We have published over 500 scholarly articles in peer-reviewed journals.
We provide cutting-edge quantitative outcome analytics for clinical and preclinical researchers and sponsors. We combine standards-based approaches with research expertise to deliver accurate, precise measures in compliance with regulatory oversight.
A key part of our mission at BNAC is to teach. We disseminate knowledge and train future neuroimagers, trained masters, and PhD students. We host fellowships for visiting doctors and research scholars. BNAC faculty have mentored and co-mentored hundreds of PhD students, MSc students, MD students, undergraduate students, neuroimaging fellows, and neurology residents.
Precise, advanced neuroimaging metrics to measure treatment effects while maximizing statistical power.
Full coordination with participating imaging centers from study initiation, individual site on-boarding, image acquisition, and analysis.
Strict adherence to the highest standards and regulatory requirements, including FDA/EMA, GCP, and ISO 9001:2015.
There is no commonly-available way for clinical neurologists to use an “everyday” MRI to provide their multiple sclerosis (MS) patients with meaningful news about their disease progression, including brain tissue changes associated with physical and cognitive impairment. The reason? Conventional MRI methods in the vast majority of clinical settings are inadequate in creating scans that can be used to measure two of the most reliable known “markers” of MS progression.
In August of this year, though, BNAC researchers published their NeuroSTREAM MSBase study. The study demonstrated that neurologists using a new, open-source software—NeuroSTREAM, recently co-developed by BNAC scientists—along with the widely-available T2-FLAIR MRI protocol, can perform and read scans that confidently assess reliable and clinically meaningful proxies of the two critical markers—salient central brain lesion volume (SCLV) and lateral ventricle volume (LVV)—in regular clinical routine settings and even in the face of complete scanner changes.
Ferdinand Schweser, Ph.D., BNAC’s Director of Sequence Development, will lead an international team exploring the link between deep gray matter iron and multiple sclerosis progression. The four-year, $1.4 million NIH-funded study will analyze thousands of MRI scans taken over 10 years to establish an objective means to assess brain iron status that could serve as part of a biomarker of MS disease progression and remission.
BNAC researchers led by Dejan Jakimovski, M.D. Ph.D., have been awarded a pilot research grant by the Consortium of Multiple Sclerosis Centers (CMSC) to determine which brain structures are responsible for specific types of cognitive decline in 100 aging MS patients. The results could open the door for researchers to monitor the most clinically relevant brain regions and potentially predict an individual patient’s risk for cognitive decline as well as appropriate treatment.
As new disease-modifying therapies extend the lives of people with multiple sclerosis by as many as 20 years or more, it becomes increasingly important to understand the causes of cognitive decline experienced by a growing percent of people with MS.
NeurologyLive®, a multimedia platform dedicated to providing health care professionals with direct access to expert-driven, practice-changing news and insights in neurology, welcomes Buffalo Neuroimaging Analysis Center to its Strategic Alliance Partnership (SAP) program.
Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS.
-Wednesday, November 11, 2020
The University at Buffalo is extremely proud of BNAC. Throughout it’s 20-year history, BNAC’s team of multidisciplinary investigators have consistently maintained funded research programs that have used innovative neuroimaging techniques to make seminal discoveries impacting the care of patients with neurological diseases. BNAC has and is making a difference
Michael E. Cain, MD, Vice President for Health Sciences and, Dean, Jacobs School of Medicine and Biomedical Sciences
BNAC’s world class research is an enormous asset for the region by attracting major funding to University at Buffalo and advancing the field of neuroimaging. The partnership between BNAC, the Clinical and Translational Science Institute and the Center for Biomedical Imaging has completely transformed translational imaging for our researchers.
Timothy F. Murphy MD, SUNY Distinguished Professor, Director, UB Clinical and Translational Science Institute
At Bristol-Myers Squibb we have been fortunate to engage with BNAC in scientific collaborations and clinical trials. Over the last 20 years, Prof. Zivadinov and his team have consistently demonstrated their passion for innovation demonstrated by their multiple publications, oral presentations and expert forums they participate in. Being at the fore front of science in neuro-imaging, BNAC scientist have developed technologies that compete amongst the best in the field and produce reliable, on-time, analysis that helps us in industry deliver innovative clinical trials for patients. As one of the best imaging centers in the world, BNAC has truly made a positive impact in neuro-imaging, we look forward to continuing drive medical discoveries with them.
Diego G. Silva, MS, VP Global Medical Head – Neurology
During the past 10 years, I have had a great opportunity to collaborate with Prof. Zivadinov and BNAC on a variety of clinical programs in the multiple sclerosis research arena. I have found the BNAC team to be very innovative in their way of thinking, and to always be applying the cutting edge of science and technology in their imaging capabilities. Moreover, their capacity to conduct various projects is multi-faceted and unique, as they are able to address critical questions in drug development and neuroimaging by various preclinical and clinical innovative explorations. The output from BNAC is always high quality, accurate, and on time. BNAC is not only able to deliver high quality project outputs, but equally so to present and publish the results at key conferences and in high quality medical journals, which helps drive forward the science of neuroimaging.
– Davorka Tomic, Senior Medical Director, Merck Group
One of the impressive characteristics of Dr. Zivadinov and his team at BNAC is the attentive ear given to people with MS – intently listening and incorporating concerns into their research pursuits. BNAC’s patient-centric focus fosters hope in those battling MS, providing assurance that their opinions matter, and that their needs are relevant in shaping today’s research. Perhaps it stems from a long history of leading MS outcomes in Buffalo, with pioneering efforts by Dr. Larry Jacobs who championed an intent focus on his patients to groundbreaking treatment that became a global standard. BNAC maintains a strong patient focus, un-wavered by contrary opinions or less popular fields of study. Their latest research initiative, CASA-MS, showcases this high regard for the patient. Collaboratively aligned with some of the best clinicians in today’s field, BNAC pursues translational research and patient guided outcomes that make a real difference for individuals with multiple sclerosis.
Larry A. Montani, BNAC Advisory Council Chair
It is an incredible opportunity to contribute to research projects in a multi-disciplinary neuroimaging lab with such an impressive scientific track record and to start my neuroscientific career with meaningful publications in translational research at BNAC.
Franziska E. Hildesheim, MRI Research Fellow